89bio Revenue and Competitors
Estimated Revenue & Valuation
- 89bio's estimated annual revenue is currently $16.1M per year.
- 89bio's estimated revenue per employee is $124,961
Employee Data
- 89bio has 129 Employees.
- 89bio grew their employee count by 29% last year.
89bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Operating Officer | Reveal Email/Phone |
2 | Chief Technical Officer | Reveal Email/Phone |
3 | Chief Operating Officer | Reveal Email/Phone |
4 | Chief Regulatory and Quality Officer | Reveal Email/Phone |
5 | CFO | Reveal Email/Phone |
6 | CEO | Reveal Email/Phone |
7 | SVP, Commercial Strategy | Reveal Email/Phone |
8 | VP, People & Culture | Reveal Email/Phone |
9 | SVP, Finance & Principal Accounting Officer | Reveal Email/Phone |
10 | VP, Clinical Develpment | Reveal Email/Phone |
89bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 15 | -32% | N/A | N/A |
#10 | $10.1M | 48 | -9% | N/A | N/A |
What Is 89bio?
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Our culture is best described by our values: • Always putting the patient first • Operating with the highest integrity and ethical standards at all times • Being authentic in all our transactions • Acting as a team – collaborating, respecting and caring for one another • Being entrepreneurial and passionate in our tasks • Being scientific and rational in our thought process and decision-making
keywords:N/A
N/A
Total Funding
129
Number of Employees
$16.1M
Revenue (est)
29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
89bio News
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver...
89bio has gained a little more confidence in its non-alcoholic steatohepatitis therapy after new data showed the treatment increased levels of a key hormone...
SAN FRANCISCO, March 24, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $22.4M | 129 | 39% | N/A |
#2 | $43.5M | 129 | -18% | N/A |
#3 | $19.4M | 129 | 11% | N/A |
#4 | $41.9M | 129 | 18% | N/A |
#5 | $12.5M | 129 | 17% | N/A |